Recs

3

Nike Wins Again: Fool by Numbers

On Sept. 20, sporting goods giant Nike (NYSE: NKE  ) released 2008 earnings for the first quarter ended Aug. 31.

  • Despite tepid sales growth in the core U.S. market -- or shrinkage in some product categories -- Nike pulled out a strong overall performance thanks to results in the rest of the world. Europe, the Middle East, and Africa improved by 16% over last year's comparable period, and the Asia Pacific region vaulted to 22% higher revenue.
  • Net income was helped by a one-time tax benefit that shaved off $0.20 per share in payments to the tax collector. On a before-tax basis, earnings improved by a more modest 16% over last year.
  • That balance sheet looks mighty strong and gives the company the fiscal freedom to keep raising its dividend payout and buying back shares.
  • With financial performances like these, it's no wonder why Adidas felt the need to boost its business with that Reebok acquisition -- to the immediate joy but long-term consternation of Motley Fool Stock Advisor subscribers (Reebok was a recommendation).

(Figures in millions, except per-share data)

Income Statement Highlights

Q1 2008

Q1 2007

Change

Sales

$4,655

$4,194

11.0%

Net Profit

$570

$377

51.0%

EPS

$1.12

$0.74

51.4%

Diluted Shares

507.3

512.0

(0.9%)

Get back to basics with the income statement.

Margin Checkup

Q1 2008

Q1 2007

Change*

Gross Margin

44.8%

44.1%

0.7

Operating Margin

14.0%

13.3%

0.7

Net Margin

12.2%

9.0%

3.3

*Expressed in percentage points

Margins are the earnings engine.

Balance Sheet Highlights

Assets

Q1 2008

Q1 2007

Change

Cash + ST Invest.

$2,791

$1,725

61.9%

Accounts Rec.

$2,774

$2,557

8.5%

Inventory

$2,155

$2,134

1.0%

Liabilities

Q1 2008

Q1 2007

Change

Accounts Payable

$972

$868

12.0%

Long-Term Debt

$421

$380

10.6%

The balance sheet reflects the company's health.

Cash Flow Highlights

Free Cash Flow

$227

$154

47.4%

Free cash flow is a Fool's best friend. Nike only gave us a tiny part of it today, and you had to tune in to its conference call for even that much.

Related Foolishness:

Best Odds in the Universe!
If you're interested in a 98.79% chance at beating the market... and a 70.84% chance at DOUBLING the market's return – Motley Fool Supernova could be just what you're looking for. And get this: We arrived at these odds from 10,000 random back-tested portfolios composed of Motley Fool Co-founder David Gardner's personal stock picks.

It's why David recently handpicked a small team of world-class portfolio managers. You see, he thinks these odds can get even better! And he'd like to prove it to you...

Simply enter your email address. And the answer to the question everybody is asking will be delivered to your inbox!


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 537235, ~/Articles/ArticleHandler.aspx, 2/13/2012 7:14:20 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 12,874.04 72.81 0.57%
S&P 500 1,351.77 9.13 0.68%
NASD 2,931.39 27.51 0.95%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

2/13/2012 4:03 PM
NKE $105.22 Down -0.19 -0.18%
Nike CAPS Rating: ****

Advertisement